Diabetes Advocate and Opinion Leader David Edelman Joins LabStyle Innovations as Product Strategy Director

RAMAT GAN, Israel, Dec. 18, 2013 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB:DRIO), developer of Dario™, a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced that diabetes advocate and opinion leader David Edelman has joined the company as the new director of product strategy. He is also the newest member of the company's scientific advisory board (SAB).

Mr. Edelman is the co-founder and president of Diabetes Daily, a leading diabetes online community with over four million annual visitors. The influential website features a diabetes magazine, community forums, and an original recipe collection. Mr. Edelman also sits on the Board of Advisors of the Diabetes Hands Foundation. He is the November 2013 recipient of the Social HealthMaker in Diabetes award. 

"Through the years, I've engaged with tens of thousands of people living with diabetes, learned their hopes, fears, struggles, and successes. I have discovered that there are a lot of things broken with how we treat diabetes, and I believe that the introduction of Dario^™ represents an important step towards fixing them," said Mr. Edelman. "I am a big believer in LabStyle's mission of helping people manage diabetes through building a smarter treatment platform. It is a pleasure to work with a smart and passionate team on such an ambitious vision to improve the lives of millions living with diabetes."  

Mr. Edelman will be helping LabStyle focus on innovating beyond merely tracking diabetes. "Some of the most innovative products, which will soon be able to sync with smart phones, are still too focused on tracking. Getting data into a smart phone, and more importantly, a cloud environment, is just the first step in a journey to transform care. Real change comes when you use that platform to help patients identify patterns, proactively recommend treatment changes, and support behavior change efforts. It's enhanced when you enable doctors to better identify patients at high-risk, to make, more frequently, better and faster clinical decisions, and to more easily, routinely follow-up. It also accelerates when health systems can automatically target resources to patients who are most likely to have acute or long-term complications," said Mr. Edelman. 

Mr. Erez Raphael, LabStyle's president and chief executive officer, agreed, "A smartphone-powered meter is the cornerstone of an ambitious program to not only provide the best tracking solution, but also the best health outcome improvement system. This is why we are in high-level talks with potential partners to expand our current solution to support medical practices, hospital systems and payers. We believe that our comprehensive vision, speed of development, and commitment to bringing together third-party device and software companies under one platform, will make Dario™ the most appealing solution for those in healthcare."

With the intention of providing the best and most useful diabetes management platform possible, LabStyle regularly turns to patients, physicians and experts in the diabetes community with a genuine interest in learning about concerns, challenges and unmet needs. Mr. Raphael continued, "This ongoing feedback helps us to better understand what is required to improve diabetes care and is proactively applied to increase the abilities and the deliverables of the Dario^™ diabetes management platform for the benefit of diabetes community. David Edelman's vast experience, respected leadership, and clear understanding of the hurdles faced by the diabetes community will certainly help us remain focused on what matters most. We are well aligned, and look forward to doing great things together. We warmly welcome David to the LabStyle team, both in his role as product strategy director and as a contributor on our SAB."

LabStyle's world roll-out of the Dario^™ diabetes management platform began on December 12^th with the market launch of the Dario^™ iOS app in the United Kingdom, Australia and New Zealand. The Dario^™ iOS app is now available in these countries for free download at the Apple app store. LabStyle remains on course to launch the Dario^™ iOS app in Italy and Belgium and the Dario^™ Android app, in the United Kingdom, New Zealand, Australia, Italy and Belgium – both during first quarter 2014. Plans are also on track to soft launch the Dario^™ all-in-one blood glucose monitoring device in the United Kingdom and in Italy during first quarter 2014.

The Dario^™ diabetes management platform includes the novel Dario^™ app (currently available for iOS and to be available in 2014 for Android), website software, and a stylish, 'all-in-one', pocket-sized, Dario^™ blood glucose monitoring device, which comes complete with lancet, strips and a glucose meter. The glucose meter connects to a smartphone and the feature rich Dario^™ mobile and website applications enabling patients, medical professionals and caregivers to access and analyze data in real time as well as from histories. 

About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) is a mobile health (mHealth) company developing and commercializing patent-pending technology providing consumers with laboratory-testing capabilities using smart phones. LabStyle's flagship product, Dario™, is a mobile, cloud-based, diabetes management platform which includes a stylish, 'all-in-one', pocket-sized, blood glucose monitoring device, iOS and Android apps and a web application. Dario™ received CE mark certification in September 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: www.mydario.com.

Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Dario™ and the Dario™ logo are trademarks owned by LabStyle Innovation Ltd.

© 2013 LabStyle Innovations Corp.  All rights reserved.

SOURCE LabStyle Innovations Corp.